GLPwatch
Victoza vs Xultophy
Drug comparison
Last updated 2026-05-28 15:46 UTCVictoza and Xultophy are both injectable diabetes medications made by Novo Nordisk, but they have different uses. Victoza contains the active ingredient liraglutide and is FDA-approved to treat type 2 diabetes and reduce cardiovascular risk. Xultophy also contains liraglutide but is combined with another drug, insulin degludec, and is only approved for treating type 2 diabetes.
AI summary of the sources below.
| Victoza | Xultophy | |
|---|---|---|
| Active ingredient | liraglutide | liraglutide |
| Manufacturer | novo-nordisk | novo-nordisk |
| Route | subcutaneous injection | subcutaneous injection |
| FDA-approved for | type 2 diabetes, cardiovascular risk reduction | type 2 diabetes |
| Label updated | 2023-02-06 | 2025-10-14 |